Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS

Akums Drugs And Pharmaceuticals — Q4 FY25 Earnings Presentation

36 slides from Akums Drugs And Pharmaceuticals's earnings presentation, May 26, 2025

  1. Slide 1: Exchange filing cover letter - Investor Presentation

    Ref: Akums/Exchange/2025-26/10 May 26, 2025 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Bandra Kurla Complex, Jeejeebhoy Towers, Dalal Street, Bandra (E),Mumbai – 400 051 Fort, Mumbai –

  2. Slide 2: Earnings Presentation May 2025

    Earnings Presentation May 2025

  3. Slide 3: Managing Directors' Message

    Managing Directors’ Message Dear Investors It gives us immense pleasure in declaring the Q4 However, despite these headwinds, Akums’ grit and and full year FY25 results of your company. While spirit shone through and we managed to maintain your company started its journey in 2004, FY25 our margins,

  4. Slide 4: Two Decades' Legacy of Expertise, Experience & Trust

    Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Quadria Capital Established R&D lab in Mumbai to manufacturing site for bought a minority Launched Akumentis to venture into regulated

  5. Slide 5: Largest India-Focused CDMO

    Largest India-Focused CDMO Akums has a strategic presence across the pharmaceutical value chain Business Share in FY25 Vertical Akums revenue CDMO Domestic Branded Formulation International Branded Formulations Trade Generics API 4

  6. Slide 6: Indian CDMO Market

    Indian CDMO Market Indian Pharma Market Share % of Indian Domestic CDMO (INR ‘000 Cr.) CDMO outsourcing Market (INR ‘000 Cr.) Large Indian domestic pharma Growing pie of CDMO CDMO expected to grow faster opportunity opportunity 39% 9.5% 13.3% 23.8 285 33% 8.4% 9.1% 28% 198 14.5 132 9.4 FY 19 FY 24 F

  7. Slide 7: Indian CDMO Market: Multiple Drivers to Accelerate Growth

    Indian CDMO Market: Multiple Drivers to Accelerate Growth “Health consumerism” driven by increasing affordability Augmented demand for specialized offerings that can be fulfilled by CDMO partners providing “customized” solutions Supplier consolidation among branded generic players Capital intensive

  8. Slide 8: CDMO Playbook

    CDMO Playbook Inputs R&D Manufacturing Global launches NO Screening of Business Case Feasibility Scale-up In-house Dossier assessment of DGCI market gaps approval Development needed? Commercialize Clinicians’ Portfolio feedback Stability YES Continuous improvement BA/BE or Clinical (IP compliance /

  9. Slide 9: The Akums Advantage

    The Akums Advantage Deep Partner Connect Extensive Infrastructure Strong R&D Focus Unwavering Quality Deep and long 11 CDMO 970+ DCGI products 350+ regulatory / client lasting relationships with manufacturing facilities approvals, 200+ first in audits in FY25; EUGMP 1,400+ clients and 1,800+ caterin

  10. Slide 10: Deep Client Connect

    Deep Client Connect Client Concentration – Top 10 CDMO Clients Length of customer relationships Optimal concentration of revenue from large customers Average relationship with top 10 customers is greater than 15 years 45.2% 43.6% 0 2 4 6 8 10 12 14 16 18 20 41.3% 38.9% 36.2% Customer 1 Customer 2 Cu

  11. Slide 11: Diversified base of Suppliers

    Diversified base of Suppliers1 Top 50 Supplier Concentration Top 50 Supplier Concentration Large "growing" base of diversified suppliers Long and stable relationship with top suppliers - 2 4 6 8 10 12 14 16 Total 1,648 1,835 Supplier 1 suppliers Supplier 2 48.6% 48.9% Supplier 3 Supplier 4 Supplier

  12. Slide 12: Technologically Advanced Manufacturing Capabilities

    Technologically Advanced Manufacturing Capabilities Annual Production Capacity (Cr units) Capacity - Dosage form wise (Cr Units) One-fourth expansion of capacity to cater to future growth Current No 4,959 Of plants 7 6 6 4 3,914 FY 25 utilization 38.5% 32.4% 34.9% 31.2% FY 21 FY 25 4,789 Asset Turns

  13. Slide 13: Technologically Advanced Manufacturing Capabilities

    Technologically Advanced Manufacturing Capabilities Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity 649 15 39 244 6 252 2,603 732 17 368 36 (Cr units) Capability Genera

  14. Slide 14: Strong R&D Focus…

    Strong R&D Focus… Continued investment in R&D (INR cr.) 20% growth in annual R&D investment consistently 3.8% 3.2% 3.1% 121.8 2.7% 2.5% 87.5 101.8 58.1 67.2 FY 21 FY 22 FY 23 FY 24 FY 25 CDMO % of revenue No of DCGI Approvals No of R&D Scientists Extensive basket of differentiated products FY 21 Tot

  15. Slide 15: … resulting in a large differentiated Product Portfolio

    … resulting in a large differentiated Product Portfolio Total number of SKUs Top 500 SKU concentration Extensive and growing portfolio Decreasing on top SKUs 21,687 57% 13,740 48% FY 21 FY 25 FY 21 FY 25 Dosage wise revenue Base v/s niche formulation (% CAGR) Strong focus across all major dosage for

  16. Slide 16: R&D Focus

    R&D Focus Illustrative Tablet Bi-layered, Inlay Multiple Tablets Pre-filled In Tablet Sustained Release Tablet in Capsule syringes Tablet in Tablet Lyophilized Smart Gummies Mouth Melting Tri Layered Vials Tablets Powders in Sachet Tablet Innovative In-house Technologies (1) As of 31st March 2025 15

  17. Slide 17: Quality Focus

    Quality Focus Regulatory Audits Client Audits 94 257 95 7 Reg audits Client Audits FY21 FY25 FY21 FY25 Key Accreditations* *Received by some or all facilities; ANVISA audit done; final confirmation is pending 16

  18. Slide 18: Competitive Positioning Vis-à-vis Domestic Peers

    Competitive Positioning Vis-à-vis Domestic Peers AKUMS Competitor 1 Competitor 2 Competitor 3 Competitor 4 Key Takeaways • Akums CDMO Revenue generates ~3/4th revenue from domestic Domestic CDMO, Pharma which is 3x CDMO Focus compared to next largest Production player Capacity • 2x capacity of the n

  19. Slide 19: CDMO Financials

    CDMO Financials CDMO revenue (INR Cr.) CDMO EBIDTA (INR Cr.) 3,208 500 454 20.0% 400 277 15.0% 2,138 10.7% 300 14.1% 10.0% 200 12.9% 5.0% 100 0 0.0% FY 21 FY 25 FY 21 FY 25 Working Capital days RoCE1,2 Net WC 85 82 18.0% 17.1% Days 87 75 68 68 73 Debtors 58 Creditors Inventory FY 21 FY 25 2021 2025

  20. Slide 20: Domestic Branded Formulations (1/2)

    Domestic Branded Formulations (1/2) MAT IPM Rank1 PCPM (INR lakhs per month) and field force Size Growth in market rank Improved productivity while expanding field coverage 58 1,483 1,306 2.43 60 2.04 FY 22 FY 25 FY 22 FY 25 Prescriber coverage Focus on specialists 2.2% 26.6% 48% 3.6% 29% 73.4% 26%

  21. Slide 21: Domestic Branded Formulation (2/2)

    Domestic Branded Formulation (2/2) Therapy Area Mix (% revenue) Brand Play (% of revenue) Strong focus on Gynae, cardiac and pediatrics Focus on large brands - 4 brands above Rs 20 cr. FY 25 47.9 52.1 Gyn FY25 Top 10 Cardiac Peadia Rest FY22 Other FY 22 45.4 54.6 Geographical Split of Revenue (FY 25

  22. Slide 22: Domestic Branded Formulation Financials

    Domestic Branded Formulation Financials Revenue (INR Cr.) EBIDTA (INR Cr.) 434 17.7% 320 10.6% 100 10.4% 77 20.0% 80 15.0% 60 40 33 10.0% 5.0% 20 - 0.0% FY 22 FY 25 FY 22 FY 25 Working Capital days RoE Net WC 64 Days 71 52.0% 128 33.8% Debtors 98 67 78 Creditors Inventory 33 21 FY 22 FY 25 FY 22 FY

  23. Slide 23: International Branded Formulations

    International Branded Formulations Geographical presence Focus countries in FY 25 - % contribution Presence across multiple markets Top countries – Uganda, Nigeria, Philippines, Myanmar, Cambodia 3.8% 2.7% 10.9% Africa 53.8 South East Asia 41.5 45.1% Rest of Asia Europe 37.5% Americas FY 22 FY 25 Nu

  24. Slide 24: International Branded Formulations Financials

    International Branded Formulations Financials Revenue (INR Cr.) EBIDTA (INR Cr.) 18.8% 19.3% 143 28 73 25.0% 14 FY 22 FY 25 FY 22 FY 25 Working Capital days RoCE1,2 5 20 84.8% 86.2% 154 138 Debtors 109 105 Creditors Inventory 2 5 FY 22 FY 25 FY 22 FY 25 1: Capital Employed= Segment assets – Segment

  25. Slide 25: Trade Generic Financials

    Trade Generic Financials Revenue (INR Cr.) EBIDTA (INR Cr.) 508 0 FY 22 FY 25 -39% -10 115 -13 -20 -30 FY 22 FY 25 -28 Trade Generics has Established “branded Beyond brand play, Higher receivables and May revisit the strategy played a key role in play” helps improve pricing to the inventory days in

  26. Slide 26: API

    API State of the art Infrastructure R&D Investment (INR Cr.) Derabassi, Lalru, Barwala, Punjab Punjab Haryana 10.0 8.4 3.9% 557 MT 180 MT - 8.0 3.9% 3.8% 6.0 4.1 3.8% Beta lactam range General APIs R&D centre 4.0 3.8% (DSIR Approved) 3.7% 2.0 3.7% 0.0 3.7% FY 22 FY 25 R&D investment % of API revenue

  27. Slide 27: API Financials

    API Financials Revenue (INR Crs) EBIDTA (INR Cr.) 219 FY 22 FY 25 109 26.1% (22) FY 22 FY 25 (44) Focus is on Building a pipeline of Target to get European Capex is largely Cost optimization improving gross export sales is a key audit done and get done; will drive initiatives to improve margins, by

  28. Slide 28: Q4 and FY24-25 Financial Performance Highlights

    Q4 and FY24-25 Financial Performance Highlights 27

  29. Slide 29: Consolidated Annual Performance Highlights

    Consolidated Annual Performance Highlights Financial Year 2025 Q4 FY25 4,170 Crs 12.3 % 5.6 % 1,073 Crs 10.4 % 4.1 % Total Income Adj. EBITDA Adj. PAT Total Income Adj. EBITDA Adj. PAT (-1.0%) (+7bps) (+38 bps) (+12.4%) (+6 bps) (-73 bps) 90.7% -566 Cr. 130 Cr. 272 Cr. OCF / EBITDA Net Debt R&D Spen

  30. Slide 30: Consolidated Quarterly Performance Highlights

    Consolidated Quarterly Performance Highlights Total Income (INR Cr.) Adjusted EBITDA1 (INR Cr) Adjusted PAT2 (INR Cr) Margin % Margin % 10.3% 12.7% 12.9% 13.3% 10.4% 4.8% 5.6% 6.4% 6.5% 4.1% 12.4 % 13.2 % -4.8 % 1,047 1,073 136 1,026 1,025 131 135 67 66 954 111 57 98 46 44 Q4 FY 24 Q1 FY 25 Q2 FY 25

  31. Slide 31: Consolidated Annual Performance Highlights

    Consolidated Annual Performance Highlights Total Income (INR Cr.) Adjusted EBITDA1 (INR Cr.) Adjusted PAT2 (INR Cr.) 4,212 4,170 Margin % Margin % 12.2% 12.3% 5.2% 5.6% 515 513 -1.0% 220 234 -0.4% 6.2%% FY 24 FY 25 FY 24 FY 25 FY 24 FY 25 Working Capital Days Operating cash flow (INR Cr.) Adj ROE/Ad

  32. Slide 32: Revenue and Margin Breakdown

    Revenue and Margin Breakdown Total Income (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) 2.1% • CDMO sales lower on account of soft API • Better gross margins driven by continued • Excluding the product development income, prices and lower volume growth focus on niche products revenue from CDMO manuf

  33. Slide 33: Segmental Quarterly Performance

    Segmental Quarterly Performance Branded Trade CDMO Revenue Export Revenue API Revenue Formulation Revenue generics Revenue 110 840 104 42 33 64 787 94 40 30 732 50 22 40 21 Q4 FY 24 Q3 FY 25 Q4 FY 25 Q4 FY 24 Q3 FY 25 Q4 FY 25 Q4 FY 24 Q3 FY 25 Q4 FY 25 Q4 FY 24 Q3 FY 25 Q4 FY 25 Q4 FY 24 Q3 FY 25 Q

  34. Slide 34: Segmental Yearly Performance

    Segmental Yearly Performance Domestic Branded International Branded Trade generics CDMO Revenue API Revenue Formulation Revenue Formulations Revenue Revenue 3,266 143 213 219 3,208 434 398 125 176 -34.9% 3.2% 8.9% 14.3% -1.8% 115 FY 24 FY 25 FY 24 FY 25 FY 24 FY 25 FY 24 FY 25 FY 24 FY 25 Domestic B

  35. Slide 35: Objects of the offer

    Objects of the offer Amount as per offer Utilization as on March Objects (Rs Cr) Unutilized Amount document 31, 2025 Repayment borrowings of Akums 159.91 159.91 - Repayment of borrowings of our 227.09 227.09 - Subsidiaries Funding incremental working capital 55.00 55.00 - requirements of our Company

  36. Slide 36: Thank You

    Thank You For further information, contact: IR Desk Akums Drugs and Pharmaceuticals Ltd investors@akums.net © 2025 All Rights Reserved. Private Limited 35

Akums Drugs and Pharmaceuticals — Q4 FY25 Earnings Presentation on 6ix